We are pleased to announce the new dates and location for the Trans-Pacific Health Sciences Dialogue: October 14-15, 2015

The Joseph B. Martin Conference Center at Harvard Medical School, Boston, MA

More information coming soon.

Take a look at some photos from the 2014 Trans-Pacific Health Sciences Dialogue!

Day 1 PhotosDay 2 Photos

About the Conference

The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.





Who Should Attend


The Trans-Pacific Health Sciences Dialogue is an event for Asian and North American senior biopharmaceutical executives, KOLs, select professional services industry advisors and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment.

Industry News from BioCentury

  • PolyPid withdraws IPOPolyPid Ltd. (Petach Tikva, Israel) withdrew its proposed IPO on NASDAQ. CBO Asaf Bar said the company is confident it could have gone public under current market conditions, but anticipates undisclosed milestones in the next few months that could boost its valuation.

    In January, PolyPid said it was seeking to sell 1.8 million shares at $10-$12 in an offering underwritten by Aegis Capital; MLV; and Chardan Capital Markets. At $11, it would have raised $20 million and been valued at $106.3 million.

    PolyPid's lead candidate is BonyPid, a biodegradable bone filler combined with an antibiotic release platform designed to treat long-bone fractures and prevent bone infection. The company plans to start a confirmatory trial of BonyPid-1000 and a pilot program for dental counterpart BonyPid-500 in Europe in 2H15.
Read more

Industry News from PharmAsia

Read more